2023 World Conference on Lung Cancer (Posters)-P1.25. Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC

P1.25. Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC - PDF(Abstract)

Back to course

Pdf Summary

A phase 2 trial was conducted to evaluate the efficacy and safety of neoadjuvant camrelizumab, in combination with chemotherapy or apatinib, for patients with resectable or potentially resectable non-small cell lung cancer (NSCLC). The study included 89 patients with stage II-III NSCLC and no EGFR/ALK alterations. Of these, 58 patients received camrelizumab plus chemotherapy, and 31 patients received camrelizumab plus apatinib. The primary endpoint of the study was major pathological response (MPR) rate. The surgery rates for camrelizumab plus chemotherapy were 78.6% for resectable disease and 50.0% for potentially resectable disease, while for camrelizumab plus apatinib, the rates were 90.0% and 42.9%, respectively. The most common reason for failure to perform surgery in potentially resectable disease cases was incomplete resectability. Among patients who underwent surgery, the efficacy outcomes showed a promising pathological response. Grade 3 or above neoadjuvant treatment-related adverse events (TRAEs) occurred in 25.9% of patients receiving camrelizumab plus chemotherapy and 12.9% of those receiving camrelizumab plus apatinib. The most common grade 3 or above TRAEs were neutrophil count decreased and alanine aminotransferase increased. In conclusion, neoadjuvant camrelizumab plus platinum-doublet chemotherapy or apatinib demonstrated manageable toxicity and promising pathological response in patients with stage II-III NSCLC, particularly in potentially resectable disease cases. This study provides evidence for the effectiveness of neoadjuvant immunotherapy in the treatment of NSCLC.

Asset Subtitle

Haoran Xia

Meta Tag

Speaker Haoran Xia

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

phase 2 trial

neoadjuvant camrelizumab

chemotherapy

apatinib

non-small cell lung cancer

NSCLC

resectable disease

potentially resectable disease

major pathological response

surgery rates